Sage Therapeutics, Inc.

NasdaqGM:SAGE Stock Report

Market Cap: US$343.2m

Sage Therapeutics Past Earnings Performance

Past criteria checks 0/6

Sage Therapeutics's earnings have been declining at an average annual rate of -9.6%, while the Biotechs industry saw earnings growing at 19.3% annually. Revenues have been declining at an average rate of 27.4% per year.

Key information

-9.6%

Earnings growth rate

-6.0%

EPS growth rate

Biotechs Industry Growth17.0%
Revenue growth rate-27.4%
Return on equity-61.2%
Net Margin-317.3%
Last Earnings Update30 Sep 2024

Recent past performance updates

Recent updates

CNS Drug Development: Same As It Ever Was

Nov 19

Sage Therapeutics: With Dalzanemdor As The Last Lifeline, Not Much Hope Left

Oct 07

Why Investors Shouldn't Be Surprised By Sage Therapeutics, Inc.'s (NASDAQ:SAGE) 25% Share Price Plunge

Aug 30
Why Investors Shouldn't Be Surprised By Sage Therapeutics, Inc.'s (NASDAQ:SAGE) 25% Share Price Plunge

Sage Therapeutics: Tremors Of Trouble, But PPD Progress (Rating Downgrade)

Jul 25

Revenues Working Against Sage Therapeutics, Inc.'s (NASDAQ:SAGE) Share Price

Jul 13
Revenues Working Against Sage Therapeutics, Inc.'s (NASDAQ:SAGE) Share Price

Sage Therapeutics Stock: Remains A Hold On Upcoming Essential Tremor Treatment Data

May 30

Is Sage Therapeutics (NASDAQ:SAGE) In A Good Position To Invest In Growth?

May 21
Is Sage Therapeutics (NASDAQ:SAGE) In A Good Position To Invest In Growth?

Analysts Have Just Cut Their Sage Therapeutics, Inc. (NASDAQ:SAGE) Revenue Estimates By 50%

Feb 22
Analysts Have Just Cut Their Sage Therapeutics, Inc. (NASDAQ:SAGE) Revenue Estimates By 50%

Calculating The Fair Value Of Sage Therapeutics, Inc. (NASDAQ:SAGE)

Feb 15
Calculating The Fair Value Of Sage Therapeutics, Inc. (NASDAQ:SAGE)

Sizing Up Sage Therapeutics

Jan 22

Things Look Grim For Sage Therapeutics, Inc. (NASDAQ:SAGE) After Today's Downgrade

Aug 09
Things Look Grim For Sage Therapeutics, Inc. (NASDAQ:SAGE) After Today's Downgrade

Here's Why We're Not Too Worried About Sage Therapeutics' (NASDAQ:SAGE) Cash Burn Situation

Feb 22
Here's Why We're Not Too Worried About Sage Therapeutics' (NASDAQ:SAGE) Cash Burn Situation

An Intrinsic Calculation For Sage Therapeutics, Inc. (NASDAQ:SAGE) Suggests It's 45% Undervalued

Nov 12
An Intrinsic Calculation For Sage Therapeutics, Inc. (NASDAQ:SAGE) Suggests It's 45% Undervalued

Here's Why We're Not Too Worried About Sage Therapeutics' (NASDAQ:SAGE) Cash Burn Situation

Oct 14
Here's Why We're Not Too Worried About Sage Therapeutics' (NASDAQ:SAGE) Cash Burn Situation

Sage Therapeutics GAAP EPS of -$2.13 beats by $0.02, revenue of $1.5M misses by $0.27M

Aug 02

We're Hopeful That Sage Therapeutics (NASDAQ:SAGE) Will Use Its Cash Wisely

Jun 15
We're Hopeful That Sage Therapeutics (NASDAQ:SAGE) Will Use Its Cash Wisely

Sage Therapeutics: Well-Funded But Uninspiring Data

Mar 24

We're Hopeful That Sage Therapeutics (NASDAQ:SAGE) Will Use Its Cash Wisely

Feb 26
We're Hopeful That Sage Therapeutics (NASDAQ:SAGE) Will Use Its Cash Wisely

Sage Therapeutics: Biogen's Backing May See It Through

Jan 04

What You Need To Know About The Sage Therapeutics, Inc. (NASDAQ:SAGE) Analyst Downgrade Today

Aug 05
What You Need To Know About The Sage Therapeutics, Inc. (NASDAQ:SAGE) Analyst Downgrade Today

Revenue & Expenses Breakdown

How Sage Therapeutics makes and spends money. Based on latest reported earnings, on an LTM basis.


Earnings and Revenue History

NasdaqGM:SAGE Revenue, expenses and earnings (USD Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
30 Sep 24106-338217-4
30 Jun 2497-4462420
31 Mar 2491-5032610
31 Dec 2386-5412750
30 Sep 2311-65628720
30 Jun 2310-5922700
31 Mar 239-5582470
31 Dec 228-5332280
30 Sep 226-5102120
30 Jun 226-5031990
31 Mar 226-4841900
31 Dec 216-4581830
30 Sep 211,1146421850
30 Jun 211,1146661720
31 Mar 211,1136371670
31 Dec 201,1146061970
30 Sep 207-5372290
30 Jun 209-6122820
31 Mar 209-6443320
31 Dec 197-6803460
30 Sep 195-6703360
30 Jun 192-6133020
31 Mar 1991-4622560
31 Dec 1890-3732010
30 Sep 1890-2841450
30 Jun 1890-2351080
31 Mar 180-28879-45
31 Dec 170-270630
30 Sep 170-2575842
30 Jun 170-2215171
31 Mar 170-18545142
31 Dec 160-159390
30 Sep 160-1323399
30 Jun 160-1183188
31 Mar 160-1082880
31 Dec 150-942569
30 Sep 150-782058
30 Jun 150-641747
31 Mar 150-471233
31 Dec 140-361024
30 Sep 140-29720
30 Jun 140-24616
31 Mar 140-21516

Quality Earnings: SAGE is currently unprofitable.

Growing Profit Margin: SAGE is currently unprofitable.


Free Cash Flow vs Earnings Analysis


Past Earnings Growth Analysis

Earnings Trend: SAGE is unprofitable, and losses have increased over the past 5 years at a rate of 9.6% per year.

Accelerating Growth: Unable to compare SAGE's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: SAGE is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (16.6%).


Return on Equity

High ROE: SAGE has a negative Return on Equity (-61.18%), as it is currently unprofitable.


Return on Assets


Return on Capital Employed


Discover strong past performing companies

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/23 10:33
End of Day Share Price 2024/12/20 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Sage Therapeutics, Inc. is covered by 39 analysts. 18 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Joel BeattyBaird
Esther Lannie HongBerenberg
null nullBMO Capital Markets Equity Research